BRCA2 and ovarian serous carcinoma: Based on these results we tested H2AX expression by immunohistochemistry using paired biopsies that we obtained from a high-grade serous ovarian carcinoma patient carrying a pathogenic somatic mutation in BRCA2 (c.3376 G > T/ p.Glu1126Ter) (Fig. 2f).